Research
Hormonal
SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce cardiovascular death, heart failure hospitalizations, and renal composite outcomes in patients with type 2 diabetes and chronic kidney disease, regardless of baseline glycemic control.
If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like empagliflozin or dapagliflozin. These medications are proven to significantly lower your risk of heart failure, kidney failure, and death, offering protection beyond just blood sugar control.
StrongSupportsVERY_HIGH confidence
The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG)-OUTCOME trial... finding that empagliflozin reduced cardiovascular death by 38% and hospitalization for HF by 35% compared with placebo... In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial... dapagliflozin reduced the composite of sustained eGFR decline, ESRD, or renal/cardiovascular death by 39%.
Why this rating
Based on large-scale randomized controlled trials (EMPA-REG, DAPA-CKD) with significant sample sizes.
Source
Cardio-Renal Metabolic Syndrome: An Integrated Approach to Prevention and Management
Adeshpal Singh et al. · Cureus · 2025
DOI 10.7759/cureus.94134
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide) reduce major adverse cardiovascular events (MACE) and nephropathy progression in high-risk patients with Type 2 Diabetes.Strong
- Lifestyle interventions (diet, exercise, weight loss, smoking cessation) significantly reduce the risk of developing Type 2 Diabetes, cardiovascular disease, and chronic kidney disease progression.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →